Literature DB >> 32680929

Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium.

Sally F Barrington1, Ben G J C Zwezerijnen2, Henrica C W de Vet3, Martijn W Heymans3, N George Mikhaeel4, Coreline N Burggraaff5, Jakoba J Eertink5, Lucy C Pike6, Otto S Hoekstra2, Josée M Zijlstra5, Ronald Boellaard2.   

Abstract

Metabolic tumor volume (MTV) is a promising biomarker of pretreatment risk in diffuse large B-cell lymphoma (DLBCL). Different segmentation methods can be used that predict prognosis equally well but give different optimal cutoffs for risk stratification. Segmentation can be cumbersome; a fast, easy, and robust method is needed. Our aims were to evaluate the best automated MTV workflow in DLBCL; determine whether uptake time, compliance or noncompliance with standardized recommendations for 18F-FDG scanning, and subsequent disease progression influence the success of segmentation; and assess differences in MTVs and discriminatory power of segmentation methods.
Methods: One hundred forty baseline 18F-FDG PET/CT scans were selected from U.K. and Dutch studies on DLBCL to provide a balance between scans at 60 and 90 min of uptake, parameters compliant and noncompliant with standardized recommendations for scanning, and patients with and without progression. An automated tool was applied for segmentation using an SUV of 2.5 (SUV2.5), an SUV of 4.0 (SUV4.0), adaptive thresholding (A50P), 41% of SUVmax (41%), a majority vote including voxels detected by at least 2 methods (MV2), and a majority vote including voxels detected by at least 3 methods (MV3). Two independent observers rated the success of the tool to delineate MTV. Scans that required minimal interaction were rated as a success; scans that missed more than 50% of the tumor or required more than 2 editing steps were rated as a failure.
Results: One hundred thirty-eight scans were evaluable, with significant differences in success and failure ratings among methods. The best performing was SUV4.0, with higher success and lower failure rates than any other method except MV2, which also performed well. SUV4.0 gave a good approximation of MTV in 105 (76%) scans, with simple editing for a satisfactory result in additionally 20% of cases. MTV was significantly different for all methods between patients with and without progression. The 41% segmentation method performed slightly worse, with longer uptake times; otherwise, scanning conditions and patient outcome did not influence the tool's performance. The discriminative power was similar among methods, but MTVs were significantly greater using SUV4.0 and MV2 than using other thresholds, except for SUV2.5.
Conclusion: SUV4.0 and MV2 are recommended for further evaluation. Automated estimation of MTV is feasible.
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  PET; lymphoma; metabolic tumor volume; standardization

Year:  2020        PMID: 32680929     DOI: 10.2967/jnumed.119.238923

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

1.  Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor.

Authors:  Gerben J C Zwezerijnen; Jakoba J Eertink; Maria C Ferrández; Sanne E Wiegers; Coreline N Burggraaff; Pieternella J Lugtenburg; Martijn W Heymans; Henrica C W de Vet; Josée M Zijlstra; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09-27       Impact factor: 10.057

2.  18F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study.

Authors:  Coreline N Burggraaff; Jakoba J Eertink; Pieternella J Lugtenburg; Otto S Hoekstra; Anne I J Arens; Bart de Keizer; Martijn W Heymans; Bronno van der Holt; Sanne E Wiegers; Simone Pieplenbosch; Ronald Boellaard; Henrica C W de Vet; Josée M Zijlstra
Journal:  J Nucl Med       Date:  2021-10-21       Impact factor: 11.082

3.  Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas.

Authors:  Wendy Revailler; Anne Ségolène Cottereau; Cedric Rossi; Rudy Noyelle; Thomas Trouillard; Franck Morschhauser; Olivier Casasnovas; Catherine Thieblemont; Steven Le Gouill; Marc André; Herve Ghesquieres; Romain Ricci; Michel Meignan; Salim Kanoun
Journal:  Diagnostics (Basel)       Date:  2022-02-06

4.  Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index.

Authors:  N George Mikhaeel; Martijn W Heymans; Jakoba J Eertink; Henrica C W de Vet; Ronald Boellaard; Ulrich Dührsen; Luca Ceriani; Christine Schmitz; Sanne E Wiegers; Andreas Hüttmann; Pieternella J Lugtenburg; Emanuele Zucca; Gerben J C Zwezerijnen; Otto S Hoekstra; Josée M Zijlstra; Sally F Barrington
Journal:  J Clin Oncol       Date:  2022-03-31       Impact factor: 50.717

5.  A comparison of FDG PET/MR and PET/CT for staging, response assessment, and prognostic imaging biomarkers in lymphoma.

Authors:  Trine Husby; Håkon Johansen; Trond Bogsrud; Kari Vekseth Hustad; Birte Veslemøy Evensen; Ronald Boellard; Guro F Giskeødegård; Unn-Merete Fagerli; Live Eikenes
Journal:  Ann Hematol       Date:  2022-02-16       Impact factor: 3.673

6.  Automatic classification of lymphoma lesions in FDG-PET-Differentiation between tumor and non-tumor uptake.

Authors:  Thomas W Georgi; Axel Zieschank; Kevin Kornrumpf; Lars Kurch; Osama Sabri; Dieter Körholz; Christine Mauz-Körholz; Regine Kluge; Stefan Posch
Journal:  PLoS One       Date:  2022-04-18       Impact factor: 3.240

7.  Combatting the effect of image reconstruction settings on lymphoma [18F]FDG PET metabolic tumor volume assessment using various segmentation methods.

Authors:  Maria C Ferrández; Jakoba J Eertink; Sandeep S V Golla; Sanne E Wiegers; Gerben J C Zwezerijnen; Simone Pieplenbosch; Josée M Zijlstra; Ronald Boellaard
Journal:  EJNMMI Res       Date:  2022-07-29       Impact factor: 3.434

8.  SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.

Authors:  Anastasios Stathis; Ulrich Mey; Sämi Schär; Felicitas Hitz; Christiane Pott; Nicolas Mach; Fatime Krasniqi; Urban Novak; Christian Schmidt; Karin Hohloch; Dirk Lars Kienle; Dagmar Hess; Alden A Moccia; Michael Unterhalt; Katrin Eckhardt; Stefanie Hayoz; Gabriela Forestieri; Davide Rossi; Stefan Dirnhofer; Luca Ceriani; Giulio Sartori; Francesco Bertoni; Christian Buske; Emanuele Zucca; Wolfgang Hiddemann
Journal:  Blood Adv       Date:  2022-07-12

9.  Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma.

Authors:  Gerben J C Zwezerijnen; Jakoba J Eertink; Coreline N Burggraaff; Sanne E Wiegers; Ekhlas A I N Shaban; Simone Pieplenbosch; Daniela E Oprea-Lager; Pieternella J Lugtenburg; Otto S Hoekstra; Henrica C W de Vet; Josee M Zijlstra; Ronald Boellaard
Journal:  J Nucl Med       Date:  2021-03-05       Impact factor: 11.082

10.  Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?

Authors:  Jakoba J Eertink; Elisabeth A G Pfaehler; Sanne E Wiegers; Tim van; Pieternella J Lugtenburg; Otto S Hoekstra; Josée M Zijlstra; Henrica C W de Vet; Ronald Boellaard
Journal:  J Nucl Med       Date:  2021-07-16       Impact factor: 10.057

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.